March 2023
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
This conference discussed the next steps for NICE in delivering innovation and supporting clinical practice in health and social care in England.
Key stakeholders and policymakers evaluated the progress made on the key ambitions outlined in the NICE Strategy 2021-26, and next steps in the priority areas of guideline development, use of real-world evidence, new approaches to health technology evaluation, and improving patient access to innovative treatments.
It was also an opportunity to discuss the way forward for NICE and their role in improving patient outcomes, supporting efforts to tackle health inequalities, and providing value for money.
We are pleased to have been able to include keynote sessions from NICE with the Chief Executive, Dr Sam Roberts; and the Director of Medical Technology, Mark Chapman - as well as a further keynote contribution from Dr Neville Young, Director of Enterprise and Innovation, Yorkshire and Humber Academic Health Science Network
The discussion took place in the context of:
- the Innovative Medicines Fund launched by DHSC in 2022, which aims to improve patient access to new medicines
- publication of the Goldacre Review and the UK Government’s Data Saves Lives strategy, which provides recommendations for use of real-world evidence to drive research and innovation
- the move to integrated care systems, with increased autonomy for local health bodies to commission services and adopt innovations
Areas for discussion included:
- NICE priorities: next steps and key issues for strategy delivery - driving development and adoption of innovative, cost-effective health technologies and treatments to improve patient outcomes
- real-world evidence:
- use of RWE to build evidence bases to inform guideline development - the role of RWE in driving forward patient access to innovation
- next steps for Secure Data Environments - developing guidance for collaboration and safe data-sharing
- the Innovative Medicines Fund: priorities for its allocation and use - maximising its effectiveness in supporting the development of new treatments
- evaluation:
- taking forward new approaches to assessing health technology - priorities for supporting efficient adoption of new developments
- further progressing collaboration between the NHS, research industry and academia - maximising patient access to medicines
- social impact:
- opportunities for developing guidelines to better support key societal priorities
- tackling health inequalities - improving patient access and safety - increasing the range of treatment options available to all patients across a wide range of conditions
The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from the Department for Business and Trade; Department of Health; DHSC; DIT; DHSC; GLD; HMPPS; HSE; MHRA; OHID; OLS; ONS; and The Scottish Government – as well as by parliamentary pass-holders from The House of Commons.
